...
首页> 外文期刊>Antiviral therapy >Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
【24h】

Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.

机译:来自未经治疗和耐拉米夫定的慢性乙型肝炎患者的乙型肝炎病毒分离株中逆转录酶和重叠的S基因的变异性。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The high degree of diversity of the hepatitis B virus (HBV) quasispecies in chronically infected individuals raises the possibility that HBV genetic variants favouring resistance to nucleosideucleotide analogues (NAs) might pre-exist to treatment. The aim of this study was to investigate the genetic variability of the entire HBV reverse transcriptase (RT) domain and of the overlapping S gene in a large series of untreated hepatitis B surface antigen carriers and in lamivudine (3TC)-resistant patients. METHODS: Sequencing analysis of the entire HBV RT domain of isolates from 100 untreated (treatment-naive group) and 59 3TC-resistant (3TC-resistant group) consecutive patients with chronic hepatitis B was performed. RESULTS: In the treatment-naive group, primary mutations known to cause resistance to NAs were not detected, but variably combined secondary/compensatory mutations were found in 46 (46%) patients. Moreover, four patients carried mutations that modified the S protein antigenicity. In the 3TC-resistant group, besides the primary 3TC-resistant mutations, various combinations of primary and secondary mutations conferring resistance to other NAs were detected in 41/59 (69.5%) patients. Importantly, the RT mutations induced by 3TC provoked stop codons in the overlapping S gene in two patients and modified the S protein antigenicity in another nine. CONCLUSIONS: This study shows that HBV mutants associated with resistance to NAs might already be present as the major infecting population in untreated patients, and that variants emerging under 3TC might also carry mutations favouring resistance to other NAs and/or potentially altering the S protein immunoreactivity.
机译:背景:慢性感染个体中乙型肝炎病毒(HBV)准种的高度多样性增加了可能对治疗产生耐药性的HBV基因变异的可能性,这些变异有利于对核苷/核苷酸类似物(NAs)的抗性。这项研究的目的是研究未经治疗的大量乙型肝炎表面抗原携带者和拉米夫定(3TC)耐药患者中整个HBV逆转录酶(RT)结构域和重叠S基因的遗传变异性。方法:对100例未经治疗(未治疗组)和59例3TC耐药(3TC耐药组)连续性慢性乙型肝炎患者分离株的整个HBV RT结构域进行了测序分析。结果:在未接受过治疗的组中,未检测到已知引起对NAs耐药的原发突变,但在46名(46%)患者中发现了可变组合的继发性/代偿性突变。此外,四名患者携带的突变改变了S蛋白的抗原性。在3TC耐药组中,除了主要的3TC耐药突变外,在41/59(69.5%)的患者中检测到了赋予其他NA耐药性的一级和二级突变的各种组合。重要的是,由3TC诱导的RT突变引起了两名患者重叠S基因的终止密码子,并改变了另外9名患者的S蛋白抗原性。结论:该研究表明,与NAs抗性相关的HBV突变体可能已经作为未治疗患者的主要感染人群而存在,并且在3TC下出现的变体也可能携带有利于对其他NAs抗性和/或可能改变S蛋白免疫反应性的突变。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号